Like in other chronic inflammatory disorders, achieving disease activity control in SLE requires the application of the treat-to-target strategy. This approach requires setting clear treatment targets ...
The patient was successfully treated with rituximab and intravenous immunoglobulin. Patients with flares of systemic lupus erythematosus (SLE), multiple organ involvement, and infections can pose a ...
DelveInsight's, “Systemic Lupus Erythematosus Pipeline Insights 2025” report provides comprehensive insights about 120+ companies and 140+ pipeline drugs in Systemic Lupus Erythematosus pipeline ...
In patients with systemic lupus erythematosus (SLE) who had been in remission for at least 1 year, immunosuppressant withdrawal was noninferior to glucocorticoid withdrawal, with no significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results